[1]
|
Nathan, D.M., Buse, J.B., Davidson, M.B., Heine, R.J., Holmann, R.R., Sherwin, R. and Zinman, B. (2006) Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 29, 1963-1972.
doi:10.2337/dc06-9912
|
[2]
|
Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R. and Zinman, B. (2009) Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32, 193-203.
doi:10.2337/dc08-9025
|
[3]
|
Bailey, C.J. (1992) Biguanides and NIDDM. Diabetes Care, 15,755-772. doi:10.2337/diacare.15.6.755
|
[4]
|
Bailey, C.J. and Turner, R.C. (1996) Metformin. The New England Journal of Medicine, 334, 574-579.
doi:10.1056/NEJM199602293340906
|
[5]
|
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G. and Gerich, J.E. (1995) Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. The New England Journal of Medicine, 333, 550-554.
doi:10.1056/NEJM199508313330903
|
[6]
|
(1995) United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. British Medical Journal, 310, 83-88.
doi:10.1136/bmj.310.6972.83
|
[7]
|
Wu, M.S., Johnston, P., Sheu, W.H., Hollenbeck, C.B., Jeng, C.Y., Goldfine, I.D., Chen, Y.D. and Reaven, G.M. (1990) Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care, 13, 1-8. doi:10.2337/diacare.13.1.1
|
[8]
|
Stang, M., Wysowski, D.K. and Butler-Jones, D. (1999) Incidence of lactic acidosis in metformin users. Diabetes Care, 22, 925-927. doi:10.2337/diacare.22.6.925
|
[9]
|
Horlen, C., Malone, R., Bryant, B., Dennis, B., Carey, T., Pignone, M. and Rothman, R. (2002) Frequency of inappropriate metformin prescriptions. Journal of the American Medical Association, 287, 2504-2505.
doi:10.1001/jama.287.19.2504-a
|
[10]
|
Calabrese, A.T., Coley, K.C., DaPos, S.V., Swanson, D. and Rao R.H. (2002) Evaluation of prescribing practices: Risk of lactic acidosis with metformin therapy. Archives of Internal Medicine, 162, 434-437.
doi:10.1001/archinte.162.4.434
|
[11]
|
Masoudi, F.A., Wang, Y., Inzucchi, S.E., Setaro, J.F., Havranek, E.P., Foody, J.M. and Krumholz, H.M. (2003) Metformin and thiazolidinedione use in Medicare patients with heart failure. Journal of the American Medical Association, 290, 81-85. doi:10.1001/jama.290.1.81
|
[12]
|
Vasisht, K.P., Chen, S.C., Peng, Y. and Bakris, G.L. (2010) Limitations of metformin use in patients with kidney disease: Are they warranted? Diabetes, Obesity and Metabolism, 12, 1079-1083.
doi:10.1111/j.1463-1326.2010.01295.x
|
[13]
|
Saydah, S.H., Loria, C.M., Eberhardt, M.S. and Brancati, F.L. (2003) Abnormal glucose tolerance and the risk of cancer death in the United States. American Journal of Epidemiology, 157, 1092-1100. doi:10.1093/aje/kwg100
|
[14]
|
Michels, K.B., Solomon, C.G., Hu, F.B., Rosner, B.A., Hankinson, S.E., Colditz, G.A. and Manson, J.E. (2003) Nurses’ Health Study. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care, 26, 1752-1758.
doi:10.2337/diacare.26.6.1752
|
[15]
|
Will, J.C., Galuska, D.A., Vinicor, F. and Calle, E.E. (1998) Colorectal cancer: Another complication of diabetes mellitus? American Journal of Epidemiology, 147, 816-825.
|
[16]
|
Everhart, J. and Wright, D. (1995) Diabetes mellitus as risk factor for pancreatic cancer: A meta-analysis. Journal of the American Medical Association, 273, 1605-1609.
doi:10.1001/jama.1995.03520440059037
|
[17]
|
Gapstur, S.M., Gann, P.H., Colangelo, L.A., Barron-Simpson, R., Kopp, P., Dyer, A. and Liu, K. (2001) Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control, 12, 763-772. doi:10.1023/A:1011279907108
|
[18]
|
Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R. and Morris A.D. (2005) Metformin and reduced risk of cancer in diabetic patients. British Medical Journal, 330, 1304-1305. doi:10.1136/bmj.38415.708634.F7
|
[19]
|
Bowker, S.L., Yasui, Y., Veugelers, P. and Johnson, J.A. (2010) Glucose-lowering agents and cancer mortality rates in type 2 diabetes: Assessing effects of time-varying exposure. Diabetologia, 53, 1631-1637.
doi:10.1007/s00125-010-1750-8
|
[20]
|
Libby, G., Donnelly, L.A., Donnan, P.T., Alessi, D.R. and Morris, A.D. (2009) Evans JMM. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-1625. doi:10.2337/dc08-2175
|
[21]
|
Moore, M.A., Park, C.B. and Tsuda, H. (1998) Implications of the hyperinsulinemia-diabetes-cancer link for preventive efforts. European Journal of Cancer Prevention, 7, 89-107.
|
[22]
|
Shaw, R.J., Lamia, K.A., Vasquez, D., Koo, S.H., Bardeesy, N., Depinho, R.A., Montminy, M. and Cantely, L.C. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310, 1642-1646. doi:10.1126/science.1120781
|
[23]
|
Isakovic, A., Harhaji, L., Stevanovic, D., Sumarac-Dumanovic, M., Starcevic, V., Micic, D. and Trajkovic, V. (2007) Dual antiglioma action of metformin: Cell cycle arrest and mitochondria-dependent apoptosis. Cellular and Molecular Life Sciences, 64, 1290-1302.
doi:10.1007/s00018-007-7080-4
|
[24]
|
Baumann, P., Mandl-Weber, S., Emmerich, B., Stranka, C. and Schmidmaler, R. (2007) Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells. Anticancer Drugs, 18, 405-410. doi:10.1097/CAD.0b013e32801416b6
|
[25]
|
Vucicevic, L., Misirkic, M., Janetovic, K., Harhaji-Trajkovic, L., Prica, M., Stevanovic, D., Isenovic, E., Sudar, E., Sumarac-Dumanovic, M., Micic, D. and Trajkovic, V. (2009) AMP-activated protein kinase-dependent and independent mechanisms underlying in vitro antiglioma action of compound C. Biochemical Pharmacology, 77, 1684-1693. doi:10.1016/j.bcp.2009.03.005
|
[26]
|
Buzzai, M., Jones, R.G., Amaravadi, R.K., Lum, J.J., DeBeradinis, R.J., Zhao, F., Viollet, B. and Thompson C.B. (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Research, 67, 6745-6752.
doi:10.1158/0008-5472.CAN-06-4447
|
[27]
|
Wolf, I., Sedetzki, S., Catane, R., Karasik, A. and Kaufman, B. (2005) Diabetes mellitus and breast cancer. Lancet Oncology, 26,103-111.
doi:10.1016/S1470-2045(05)01736-5
|
[28]
|
Liu, B., Fan, Z., Edgerton, S.M., Deng, X.S., Alimova, I.N., Lind, S.E. and Thor, A.D. (2009) Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle, 8, 2031-2040.
doi:10.4161/cc.8.13.8814
|
[29]
|
Alimova, I.N., Liu, B., Fan, Z., Edgerton, S.M., Dillion, T., Lind, S.E. and Thor, A.D. (2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle, 8, 909-915.
doi:10.4161/cc.8.6.7933
|
[30]
|
Sachdev, D., Singh, R., Fujita-Yamaguchi, Y. and Yee, D. (2006) Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: Implication for anti-insulin-like growth factor therapy in breast cancer. Cancer Research, 66, 2391-2402.
doi:10.1158/0008-5472.CAN-05-3126
|
[31]
|
Zakikhani, M., Dowling, R., Fantus, G., Pollak, M. and Sonenberg, N. (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research, 66, 10269-10273.
doi:10.1158/0008-5472.CAN-06-1500
|
[32]
|
Rattan, R., Giri, S., Hartmann, L.C. and Shridhar, V. (2011) Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. Journal of Cellular and Molecular Medicine, 15, 166-178.
doi:10.1111/j.1582-4934.2009.00954.x
|
[33]
|
Calle, E.E., Rodriguez, C., Walker-Thurmond, K. and Thun, M.J. (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England Journal of Medicine, 348, 1625-1638.
doi:10.1056/NEJMoa021423
|
[34]
|
Dronavalli, S. and Ehrmann, D.A. (2007) Pharmacologic therapy of polycystic ovary syndrome. Clinical Obstetrics and Gynecology, 50, 244-254.
doi:10.1097/GRF.0b013e31802f35a0
|
[35]
|
Mutter, G.L., Lin, M.C., Fitzgerald, J.T., Kim, J.B., Baak, J.P., Lees, J.A., Weng, L.P. and Eng, C. (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. Journal of the National Cancer Institute, 92, 924-930. doi:10.1093/jnci/92.11.924
|
[36]
|
Lu, K.H., Wu, W., Dave, B., Slomovitz, B.M., Buruke, T.W., Munsell, M.F., Broaddus, R.R. and Walker, C.L. (2008) Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clinical Cancer Research, 14, 2543-2450. doi:10.1158/1078-0432.CCR-07-0321
|
[37]
|
Cantrell, L.A., Zhou, C., Mendivil, A., Malloy, K.M., Gehrig, P.A. and Bae-Jump, V.L. (2010) Metformin is a potent inhibitor of endometrial cancer cell proliferation—Implications for a novel treatment strategy. Gynecologic Oncology, 116, 92-98. doi:10.1016/j.ygyno.2009.09.024
|
[38]
|
Zhou, C., Gehrig, P.A., Whang, Y.E. and Boggess, J.F. (2003) Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Molecular Cancer Therapeutics, 2, 789-795.
|
[39]
|
Xie, Y., Wang, Y.L., Yu, L., Hu, Q., Ji, L., Zhang, Y. and Liao, Q.P. (2011) Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 126, 113-120. doi:10.1016/j.jsbmb.2010.12.006
|
[40]
|
Scheen, A.J. (1996) Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics, 30, 359-371.
doi:10.2165/00003088-199630050-00003
|
[41]
|
Wilcock, C. and Bailey, C.J. (1994) Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica, 24, 49-57.
doi:10.3109/00498259409043220
|
[42]
|
Koepsell, H., Lips, K. and Volk, C. (2007) Polyspecific organic transporters: Structure, function, physiologic roles, and biopharmaceutical implications. Pharmaceutical Research, 24, 1227-1251. doi:10.1007/s11095-007-9254-z
|
[43]
|
Shu, Y., Sheardown, S., Brown, C., Owen, R.P., Zhang, S., Castro, R.A., Ianculescu, A.G., Yue, L., Lo, J.C., Burchard, E.G., Brett, C.M. and Glacomini, K.M. (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. Journal of Clinical Investigation, 117, 1422-1431. doi:10.1172/JCI30558
|